Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose acellular pertussis-diphtheria-tetanus (Tdap) combined vaccine in ≥6-year-olds
CTR20260555Phase 2Active
- Sponsor
- Institute of Medical Biology Chinese Academy of Medical Sciences
- Start
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tetanus toxoid + diphtheria toxoid + acellular pertussis vaccine (reduced antigen content) in pertussis, diphtheria, Tetanus, sponsored by Institute of Medical Biology Chinese Academy of Medical Sciences. Started Mar 2026; status: active.
02
Drugs
tetanus toxoid + diphtheria toxoid + acellular pertussis vaccine (reduced antigen content)
03
Conditions
pertussisdiphtheriaTetanus
Beyond the preview
Go deeper on CTR20260555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260555.